New Strategies for Multimodality Therapy in Treating Locally Advanced Cervix Cancer

Jonathan Verma, Bradley J. Monk, Aaron Wolfson

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

Cervical cancer is the fourth most common cause of cancer of women worldwide. In the developing world, it comprises 12% of all cancers of women. Since 1999, the mainstay of treatment for locally advanced cervical cancer (LACC) has been concurrent cisplatin-based chemoradiation. However, outcomes in this disease remain suboptimal, with long-term progression-free survival and overall survival rates of approximately 60%. There are several new strategies of combined modality treatment under evaluation in LACC, including chemotherapy before and after treatment as well as novel agents such as poly-adenosine diphosphate ribose polymerase inhibitors, antiangiogenic blockage, and immunotherapy. We provide a brief overview of these strategies and their potential in the treatment of women with LACC.

Original languageEnglish (US)
Pages (from-to)344-348
Number of pages5
JournalSeminars in Radiation Oncology
Volume26
Issue number4
DOIs
StatePublished - Oct 1 2016

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'New Strategies for Multimodality Therapy in Treating Locally Advanced Cervix Cancer'. Together they form a unique fingerprint.

Cite this